Cancer Drug Doses: Less Is More?

A growing movement of researchers, doctors, and patients is advocating for studies to optimize cancer drug dosages, suggesting that lower doses could prevent severe side effects and save billions. For instance, Northwestern University economist Chuck Manski stopped his immunotherapy treatment due to severe side effects, a decision aligned with practices in other countries using reduced or altered dosing schedules.

Despite potential benefits, pharmaceutical companies show little interest in reducing dosages, as higher sales mean more profit. Studies estimate billions could be saved annually if minimum necessary dosages were used. This profit-driven approach means dose-optimization studies rarely occur after a drug enters the market.

While the U.S. FDA has issued guidelines to encourage companies to conduct more precise dosing studies before drug approval, it cannot compel post-approval studies or influence drug pricing. Consequently, only poorer countries like India are extensively testing ultralow doses, yielding promising results but lacking direct comparison to standard U.S. treatments.

Many patients experience debilitating side effects, leading to extreme measures like selling homes to afford insurance and treatment. Patient advocates are working with drug companies and researchers to gather data on dosage reductions, emphasizing the need for transparency to help patients make informed decisions about their quality of life.